[pubmed] Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
Posté : 13 juil. 2020 12:00
Vélez-Santamaría V, et al. Ther Adv Neurol Disord 2020.
ABSTRACT
Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.
PMID:32655688 | PMC:PMC7331764 | DOI:10.1177/1756286420932035
Source: https://pubmed.ncbi.nlm.nih.gov/3265568 ... 9&v=2.10.1